MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/20543581251348187

Медицинская библиотека · Canadian journal of kidney health and disease · 2025

The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol.

Walsh Michael, Collister David, Gallagher Martin, Mark Patrick B, de Zoysa Janak R, Tyrwhitt Jessica, Tennankore Karthik, Sola Laura, Reis Gilmar, Xavier Denis, Villanueva Russell, Liu Wen J, Félix Camilo, Zuo Li, Arici Mustafa, Jha Vivekanand, Wald Ron, Wang Amanda Y, Faruqui Atiya R, Yuan Fei, Lee Shun Fu, Kuptsova Alena, Christou Courtney, Devereaux P J, ACHIEVE Investigators

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. Whether spironolactone, a mineralocorticoid receptor antagonist, improves outcomes for patients receiving maintenance dialysis is unclear.

OBJECTIVE

To assess the efficacy and safety of spironolactone in patients receiving maintenance dialysis.

DESIGN

Placebo-controlled, randomized controlled trial.

SETTING

Dialysis units.

PATIENTS: Patients receiving maintenance dialysis who are adherent to and able to tolerate spironolactone 25 mg daily during an open-label run-in period of at least 49 days were randomized to spironolactone 25 mg daily or matching placebo.

MEASUREMENTS: Randomized participants were followed for the primary outcome of cardiovascular death or hospitalization due to heart failure. Secondary outcomes include cause specific deaths, hospitalization due to heart failure, all-cause death, all-cause hospitalizations, and severe hyperkalemia. All deaths and possible hospitalizations for heart failure were adjudicated.

METHODS

Eligible participants received open-label spironolactone 25 mg daily for at least 7 weeks during a run-in period. Participants who tolerated and adhered to treatment were randomly allocated to continue spironolactone 25 mg daily or a matching placebo. We followed participants until trial close.

RESULTS

The trial began recruitment in 2018 and concluded recruitment in December 2024. Despite a reduced rate of recruitment during the global COVID-19 pandemic 3565 eligible participants were enrolled of whom 2538 were randomized to spironolactone or placebo from 143 dialysis programs.

LIMITATIONS: Limited funding and the trial was stopped early due to futility to demonstrate an effect.

CONCLUSIONS

ACHIEVE was designed as a large, simple trial to determine if spironolactone 25 mg daily prevents cardiovascular mortality and heart failure hospitalizations in patients with kidney failure receiving maintenance dialysis. ACHIEVE demonstrates the possibility of conducting large, international, investigator initiated randomized controlled trials for patients with kidney failure receiving dialysis.NCT03020303.

Для цитирования: Walsh Michael, Collister David, Gallagher Martin, Mark Patrick B, de Zoysa Janak R, Tyrwhitt Jessica, Tennankore Karthik, Sola Laura, Reis Gilmar, Xavier Denis, Villanueva Russell, Liu Wen J, Félix Camilo, Zuo Li, Arici Mustafa, Jha Vivekanand, Wald Ron, Wang Amanda Y, Faruqui Atiya R, Yuan Fei, Lee Shun Fu, Kuptsova Alena, Christou Courtney, Devereaux P J, ACHIEVE Investigators. The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol.. Canadian journal of kidney health and disease. 2025. DOI: 10.1177/20543581251348187.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.